Biosimilar assessment a goal of FDA modernisation plan
The FDA is prioritising development of technologies to compare biosimilars to innovator products in its plan to modernise regulatory science.
Archives for August 17, 2011
Bioprocessing unit sale could help Repligen, investor says
Repligen should consider selling its bioprocessing unit, which sells materials used in mAb production, to make best use of its assets, a shareholder suggests.